Repeat 18F-FDG PET for monitoring neoadjuvant chemotherapy in patients with stage III non-small cell lung cancer

This publication has 26 references indexed in Scilit:

• Prognostic Relevance of Response Evaluation Using [¹⁸F]-2-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography in Patients With Locally Advanced Non–Small-Cell Lung Cancer
  Journal of Clinical Oncology, 2005
• Value of F-18-fluorodeoxyglucose positron emission tomography after induction therapy of locally advanced bronchogenic carcinoma
  The Journal of Thoracic and Cardiovascular Surgery, 2004
• Repeat FDG-PET After Neoadjuvant Therapy is a Predictor of Pathologic Response in Patients With Non-Small Cell Lung Cancer
  The Annals of Thoracic Surgery, 2004
• The Role of PET Scan in Diagnosis, Staging, and Management of Non-Small Cell Lung Cancer
  The Oncologist, 2004
• Posttherapy [¹⁸F] Fluorodeoxyglucose Positron Emission Tomography in Carcinoma of the Cervix: Response and Outcome
  Journal of Clinical Oncology, 2004
• Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation
  Blood, 2003
• The value of [18F]fluoro-2-deoxy-?-glucose positron emission tomography in the selection of patients with stage IIIA-N2 non-small cell lung cancer for combined modality treatment
  Lung Cancer, 2003
• Response evaluation criteria in solid tumors (RECIST): New guidelines
  Medical and Pediatric Oncology, 2001
• Incidence of local recurrence and second primary tumors in resected stage I lung cancer
  The Journal of Thoracic and Cardiovascular Surgery, 1995
• Whole-body 18F-fluorodeoxyglucose positron emission tomography in preoperative evaluation of lung cancer
  The Lancet, 1994